Cargando…

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Detalles Bibliográficos
Autores principales: Bichet, Daniel G., Aerts, Johannes M., Auray-Blais, Christiane, Maruyama, Hiroki, Mehta, Atul B., Skuban, Nina, Krusinska, Eva, Schiffmann, Raphael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790740/
https://www.ncbi.nlm.nih.gov/pubmed/33219325
http://dx.doi.org/10.1038/s41436-020-01041-5
_version_ 1783633484487589888
author Bichet, Daniel G.
Aerts, Johannes M.
Auray-Blais, Christiane
Maruyama, Hiroki
Mehta, Atul B.
Skuban, Nina
Krusinska, Eva
Schiffmann, Raphael
author_facet Bichet, Daniel G.
Aerts, Johannes M.
Auray-Blais, Christiane
Maruyama, Hiroki
Mehta, Atul B.
Skuban, Nina
Krusinska, Eva
Schiffmann, Raphael
author_sort Bichet, Daniel G.
collection PubMed
description
format Online
Article
Text
id pubmed-7790740
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-77907402021-01-15 Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease Bichet, Daniel G. Aerts, Johannes M. Auray-Blais, Christiane Maruyama, Hiroki Mehta, Atul B. Skuban, Nina Krusinska, Eva Schiffmann, Raphael Genet Med Correction Nature Publishing Group US 2020-11-20 2021 /pmc/articles/PMC7790740/ /pubmed/33219325 http://dx.doi.org/10.1038/s41436-020-01041-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Correction
Bichet, Daniel G.
Aerts, Johannes M.
Auray-Blais, Christiane
Maruyama, Hiroki
Mehta, Atul B.
Skuban, Nina
Krusinska, Eva
Schiffmann, Raphael
Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
title Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
title_full Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
title_fullStr Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
title_full_unstemmed Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
title_short Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
title_sort correction: assessment of plasma lyso-gb(3) for clinical monitoring of treatment response in migalastat-treated patients with fabry disease
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790740/
https://www.ncbi.nlm.nih.gov/pubmed/33219325
http://dx.doi.org/10.1038/s41436-020-01041-5
work_keys_str_mv AT bichetdanielg correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT aertsjohannesm correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT aurayblaischristiane correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT maruyamahiroki correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT mehtaatulb correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT skubannina correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT krusinskaeva correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease
AT schiffmannraphael correctionassessmentofplasmalysogb3forclinicalmonitoringoftreatmentresponseinmigalastattreatedpatientswithfabrydisease